Back

Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial

3 September 2019 (08:48 - 08:57)
Organised by:
Congress Presentation Part of: Lipids / Cardiovascular risk prediction / Life style Drug therapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor David Kallend

The Medicines Company, Zurich (Switzerland)

9 More presentations in this session

Presentation thumbnail
Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.
Ms B. Heidemann (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
The contribution of familial hypercholesterolemia (FH) to premature coronary artery disease decreased by 2-fold between 1998 and 2018 in a founder population with high prevalence of FH
Doctor A. Lauziere (Chicoutimi, CA)
Abstract Slides Video
Presentation thumbnail
The effects of climate and air pollutants on heart failure hospitalizations and mortality (CLIMATE-HF Study)
Doctor W. Ngampongpan (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Association between secondhand smoke exposure and diabetes mellitus in 131,724 Korean never smokers using self-reported questionnaire and cotinine: gender differences
Doctor J. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Irregular eating behavior and incidence of cardiovascular disease: results from a swedish 60-year-old cohort of men and women.
Doctor F. Laguzzi (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids / Cardiovascular risk prediction / Life style

The Event

Event poster

ESC Congress 2019

3 September 2019 08:48 CET
You may be interested in
thumbnail
Congress Presentation
Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11)
30 August 2020
thumbnail
Congress Presentation
Lipoprotein(a), are its levels really invariable?
25 April 2024
thumbnail
Congress Presentation
New treatment options for lipoprotein(a).
27 August 2022
thumbnail
Congress Presentation
Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources